Patents by Inventor Peter Fey

Peter Fey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12202805
    Abstract: The present invention relates to a novel and improved process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluo-romethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of the formula (I) and to novel crystalline forms of it, which is i.a. the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), furthermore the present invention relates to a novel and selective crystallization process for preparation of the pseudopolymorphic form monohydrate I (I-M-I) or the pseudopolymorphic form monohydrate II (I-M-II), preferably monohydrate I of formula (I-M-I) and to pharmaceutical compositions comprising monohydrate I of formula (I-M-I) and to its use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of pulmonary and cardiopulmonary and cardiovascular diseases.
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: January 21, 2025
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Britta Olenik, Birgit Keil, Bernd Rösler, Peter Fey, Heiko Schirmer, Guido Becker, Julian Egger, Clemens Bothe, Helene Faber
  • Patent number: 12172996
    Abstract: The present invention relates to methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate in the form of a novel active compound product having improved properties, for example in respect of the isolability of the active compound product, the dischargeability of the active compound product after isolation and drying and also conveyability, sieveability and micronizability of the active compound product, and to processes for the production and formulation thereof.
    Type: Grant
    Filed: December 16, 2019
    Date of Patent: December 24, 2024
    Assignee: Adverio Pharma GmbH
    Inventors: Peter Fey, Michal Sowa, Joerg Brockob, Markus Longerich, Guido Becker, Heike Neumann
  • Patent number: 12138256
    Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmon
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: November 12, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Eva Maria Becker-Pelster, Hanna Tinel, Michael Hahn, Dieter Lang, Gerrit Weimann, Johannes Nagelschmitz, Lisa Dietz, Soundos Saleh, David Jung, Ildiko Terebesi, Tobias Mundry, Annett Richter, Britta Olenik, Birgit Keil, Bernd Rösler, Peter Fey, Heiko Schirmer, Guido Becker, Clemens Bothe, Helene Faber, Julian Egger, Mark Parry, David Ward, Cecile Vitre
  • Patent number: 11760737
    Abstract: The present application relates to a novel, cost-saving and efficient process for preparing 4-(2,2,3,3-tetrafluoropropyl)morpholine which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: September 19, 2023
    Assignee: ADVERIO PHARM GmbH
    Inventors: Peter Fey, Sergii Pazenok, Christian Funke, Natalya Pavlovna Kolesnik, Olexandr Ivanovich Guzyr, Yuriy Grigorievich Shermolovich
  • Publication number: 20220234996
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Application
    Filed: April 18, 2022
    Publication date: July 28, 2022
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Küsel, Felix Spindler
  • Patent number: 11332435
    Abstract: The present invention relates to a novel and improved process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid of the formula (I), to the compound of the formula (I) in crystalline form and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular, cardiopulmonary and cardiorenal disorders.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: May 17, 2022
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter Fey, Philipp Rubenbauer, Kai Lovis, Britta Olenik, Julia Kusel, Felix Spindler
  • Patent number: 11332444
    Abstract: Quinolonecarboxylic esters of the general formula (II) are hydrolyzed to quinolonecarboxylic acids of the general formula (I): The method comprises the step A): A) reacting compounds of the formula (II) with a mixture comprising acetic acid, sulfuric acid and water In step A), ?30 to ?40 mol of acetic acid, ?0.3 to ?1 mol of sulfuric acid and ?0.9 to ?2.5 mol of water are used per mole of compounds of the formula (II). The method is particularly suitable for the synthesis of the intermediate (I) in the synthesis of pradofloxacin.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 17, 2022
    Assignee: Bayer Animal Health GmbH
    Inventors: Peter Fey, Mathias Berwe, Joerg Wirths, Ralf Wischnat, Markus Longerich, Antje Dietzel
  • Publication number: 20220089554
    Abstract: The present application relates to a novel, cost-saving and efficient process for preparing 4-(2,2,3,3-tetrafluoropropyl)morpholine which serves as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: January 15, 2020
    Publication date: March 24, 2022
    Applicant: Adverio Pharma GmbH
    Inventors: Peter Fey, Sergii Pazenok, Christian Funke, Natalya Pavlovna Kolesnik, Olexandr Ivanovich Guzyr, Yuriy Grigorievich Shermolovich
  • Publication number: 20220048907
    Abstract: The present invention relates to methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate in the form of a novel active compound product having improved properties, for example in respect of the isolability of the active compound product, the dischargeability of the active compound product after isolation and drying and also conveyability, sieveability and micronizability of the active compound product, and to processes for the production and formulation thereof.
    Type: Application
    Filed: December 16, 2019
    Publication date: February 17, 2022
    Applicant: Adverio Pharma GmbH
    Inventors: Peter Fey, Michal Sowa, Joerg Brockob, Markus Longerich, Guido Becker, Heike Neumann
  • Patent number: 10633357
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 28, 2020
    Assignee: ADVERIO PHARMA GMBH
    Inventor: Peter Fey
  • Patent number: 10633356
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 28, 2020
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Peter Fey, Alfons Grunenberg, Donald Bierer
  • Patent number: 10364229
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: July 30, 2019
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Peter Fey, Alfons Grunenberg, Donald Bierer
  • Patent number: 9845300
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: December 19, 2017
    Assignee: ADVERIO PHARMA GMBH
    Inventor: Peter Fey
  • Patent number: 9604948
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 28, 2017
    Assignee: ADVERIO PHARMA GMBH
    Inventors: Peter Fey, Alfons Grunenberg, Donald Bierer
  • Patent number: 9328066
    Abstract: The present invention relates to a novel enantioselective method of preparing (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-5 methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: May 3, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Peter Fey, Agathe Christine Mayer
  • Patent number: 9150573
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: October 6, 2015
    Assignee: Adverio Pharma GmbH
    Inventor: Peter Fey
  • Patent number: 8802847
    Abstract: The present application relates to a novel and efficient process for preparing novel substituted 5-fluoro-1H-pyrazolopyridines of the formula (VI) which are suitable as an intermediate for production of medicaments and for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders. More particularly, the 5-fluoro-1H-pyrazolopyridines of the formula (VI) are suitable for preparation of the compound of the formula (I) which serves for production of medicaments, for production of medicaments for treatment and/or prophylaxis of cardiovascular disorders.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: August 12, 2014
    Assignee: Bayer Intellectual Property GmbH
    Inventor: Peter Fey
  • Publication number: 20140155637
    Abstract: The present invention relates to a novel enantioselective method of preparing (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-5 methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide, to novel intermediate compounds, and to the use of said novel intermediate compounds for the preparation of said (S)- and (R)-enantiomers of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamide.
    Type: Application
    Filed: May 24, 2012
    Publication date: June 5, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Peter Fey, Agathe Christine Mayer
  • Patent number: 7379265
    Abstract: A base support member for a disc drive is provided. The base support member includes a disc support cavity configured to house and support a spinning disc, and a filter support cavity configured to house and support a filter. The base support member also includes at least one surface that defines an airborne filtering channel that is generally disposed within the filter support cavity of the base support member. The airborne filtering channel has an inlet opening positioned in a first location proximate the disc support cavity and an outlet opening positioned in a second location proximate the disc support cavity. The airborne filtering channel is configured to receive a flow of air from the spinning disc at the inlet opening, pass the flow of air through the filter cavity and to discharge the flow of air at the outlet opening.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: May 27, 2008
    Assignee: Seagate Technology LLC
    Inventors: (Peter) Fei Wang, Stephen P. LeClair, Steven D. Knopp, Robert W. Mead
  • Patent number: 6987185
    Abstract: The enantiomers of methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl)-1,4-dihydro-5-pyrimidinecarboxylate can be separated with the aid of (?)-camphanic acid.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: January 17, 2006
    Assignee: Bayer HealthCare AG
    Inventors: Siegfried Goldmann, Peter Fey